The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
285 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $62,905,605 in first-year total cost, median $218,089.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-P (O1)]21
- Special Emphasis Panel[ZCA1 SRB-A (M1)]16
- Special Emphasis Panel[ZCA1 SRB-A (J1)]13
- Special Emphasis Panel[ZCA1 SRB-F (O2)]12
- Special Emphasis Panel[ZCA1 SRB-K (J2)]11
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR14
- DUKE UNIVERSITY9
- H. LEE MOFFITT CANCER CTR & RES INST9
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH7
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE6
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Novel circulating biomarker digital scores for assessing treatment response in liver cancer1R21CA280444-01 | YANG, JU DONGZHU, YAZHEN | CEDARS-SINAI MEDICAL CENTER, CA | $436,472 | ZCA1 |
| 2023 | Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy1R21CA270913-01A1 | ELKENAWI, ASMAA | INDIANA UNIVERSITY INDIANAPOLIS, IN | $423,130 | ZCA1 |
| 2023 | A lung cancer vaccine based on exosomes of induced pluripotent stem cells1R21CA280453-01 | LI, CHIYADDANAPUDI, KAVITHA | UNIVERSITY OF LOUISVILLE, KY | $402,401 | ZCA1 |
| 2023 | The paradox of myeloid leukemia of Down syndrome1R21CA270718-01A1 | GE, YUBINTAUB, JEFFREY WARREN | WAYNE STATE UNIVERSITY, MI | $395,973 | ZCA1 |
| 2023 | Understanding how the interaction between Lag3 deficiency and hypercholesterolemia impact anti-tumor immunity and cardiovascular disease in a melanoma model1R21CA279098-01 | ADLER, ADAM JRODRIGUEZ, ANNABELLE | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $271,004 | ZCA1 |
| 2023 | Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy1R21CA280367-01 | PERNA, FABIANA | H. LEE MOFFITT CANCER CTR & RES INST, FL | $270,783 | ZCA1 |
| 2023 | Translation initiation as a therapeutic target in neuroblastoma1R21CA267521-01A1 | GEORGE, RANI E. | DANA-FARBER CANCER INST, MA | $258,761 | ZCA1 |
| 2023 | A new highly sensitive targeted imaging method for early tumor detection1R21CA274007-01A1 | RADU, AURELIAN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $258,238 | ZCA1 |
| 2023 | Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing1R21CA280520-01 | YEUNG, CECILIA C | FRED HUTCHINSON CANCER CENTER, WA | $255,809 | ZCA1 |
| 2023 | Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways1R21CA280446-01 | GOLEMIS, ERICA A.WARD, SARA J | RESEARCH INST OF FOX CHASE CAN CTR, PA | $255,105 | ZCA1 |
| 2023 | Tumor-targeted disruption of mismatch repair in microsatellite stable colorectal cancer1R21CA277460-01 | LIEBERMAN, JUDY | BOSTON CHILDREN'S HOSPITAL, MA | $248,243 | ZCA1 |
| 2023 | Molecular biomarkers of future aggressive behavior in pituitary tumors1R21CA280469-01 | LIN, ANDREW | SLOAN-KETTERING INST CAN RESEARCH, NY | $248,243 | ZCA1 |
| 2023 | A Prostate Cancer Dependency Map to Identify Tumor Subtype-Specific Vulnerabilities1R21CA277368-01 | NELSON, PETER S | FRED HUTCHINSON CANCER CENTER, WA | $246,840 | ZCA1 |
| 2023 | Differentiation of tumor progression from radiation necrosis using MR cell size imaging1R21CA270731-01A1 | XU, JUNZHONG | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $245,438 | ZCA1 |
| 2023 | Targeting Autocrine Hepatocyte Growth Factor (HGF) Production as a Therapeutic Modality in Acute Myeloid Leukemia (AML)1R21CA263337-01A1 | BLASER, BRADLEY WAYNEWANG, VICTORIA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $238,101 | ZCA1 |
| 2023 | TERT epigenetic and genomic variants in stage II melanoma as biomarkers of outcome1R21CA277480-01 | POLSKY, DAVID | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $237,724 | ZCA1 |
| 2023 | Targeting FL3 and SRC kinases for AML therapy1R21CA252366-01A1 | REDDY, E PREMKUMAR | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $237,023 | ZCA1 |
| 2023 | Disease-homing light delivery by engineering bioluminescent immune cells for whole body precision photomedicine1R21CA263452-01A1 | SPRING, BRYAN QUILTY | NORTHEASTERN UNIVERSITY, MA | $236,444 | ZCA1 |
| 2023 | Developing GRB2-PROTACs for Treatment of Lung Cancer1R21CA267283-01A1 | JI, HAITAO MARK | H. LEE MOFFITT CANCER CTR & RES INST, FL | $236,321 | ZCA1 |
| 2023 | Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets1R21CA277288-01 | MONASTYRSKYI, ANDRIIRIX, UWE | H. LEE MOFFITT CANCER CTR & RES INST, FL | $236,321 | ZCA1 |
| 2023 | DNASE1L3 regulation of anti-tumor immune responses following radiation therapy1R21CA277250-01 | GOUGH, MICHAEL JAMES | PROVIDENCE HEALTH & SERVICES - OREGON, WA | $234,218 | ZCA1 |
| 2023 | Patient-Centered Insights from the POWER Trial: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform Radiation Therapy Decisions in Older Women with Early-Stage Breast Cancer1R21CA277311-01 | SHOWALTER, SHAYNA LEFRAK | UNIVERSITY OF VIRGINIA, VA | $233,661 | ZCA1 |
| 2023 | Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma1R21CA273282-01A1 | SKAPEK, STEPHEN XXU, LIN | UT SOUTHWESTERN MEDICAL CENTER, TX | $230,010 | ZCA1 |
| 2023 | The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate Cancer1R21CA273501-01A1 | DENMEADE, SAMUEL RSANIN PENA, DAVID ESTEBAN | JOHNS HOPKINS UNIVERSITY, MD | $229,659 | ZCA1 |
| 2023 | Preclinical assessment of efficacy and tumor microenvironment alterations by PPRX-1701 in glioblastoma1R21CA259734-01A1 | LAWLER, SEAN EDWARD | BROWN UNIVERSITY, RI | $229,519 | ZCA1 |
| 2023 | A novel gene therapy approach targeting STING-silenced cold tumors1R21CA267803-01A1 | YOU, JIANXIN | UNIVERSITY OF PENNSYLVANIA, PA | $227,906 | ZCA1 |
| 2023 | Identifying Novel Radiation Sensitizers in Cervical Cancer1R21CA277332-01 | COLBERT, LAUREN ELIZABETH | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2023 | Enhancing CAR T Cell Homing Through Glycoengineering1R21CA270491-01A1 | AL-ATRASH, GHEATH | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2023 | First-in-Human Imaging of Innate Immunity Activation with a Redox-Tuned PET Reporter1R21CA277283-01 | PIWNICA-WORMS, DAVID | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2023 | Investigating the Effect of FLASH-Radiotherapy on Tumor and Normal Tissue1R21CA273845-01A1 | FRANK, STEVEN JAY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2023 | Combined bromodomain and CDK4/6 inhibition in NUT Carcinoma and other solid tumors1R21CA277316-01 | CHENG, MICHAEL L. | DANA-FARBER CANCER INST, MA | $226,502 | ZCA1 |
| 2023 | Sieve based full likelihood approach for the Cox proportional hazards model with applications to immunotherapies trials1R21CA263950-01A1 | HALABI, SUSANWU, YUAN | DUKE UNIVERSITY, NC | $225,803 | ZCA1 |
| 2023 | Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings1R21CA273832-01A1 | KELLEHER, SARAH | DUKE UNIVERSITY, NC | $225,803 | ZCA1 |
| 2023 | Target the Dusp1 in Jak2 dependent myeloproliferative neoplasm (MPN) for curative treatment1R21CA280723-01 | AZAM, MOHAMMAD | CINCINNATI CHILDRENS HOSP MED CTR, OH | $225,101 | ZCA1 |
| 2023 | Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients1R21CA277285-01 | POLLACK, SETH M | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $224,400 | ZCA1 |
| 2023 | Rapid Response Monitoring with Circulating Tumor DNA in Metastatic Breast Cancer1R21CA280472-01 | MILES, GEORGE | BAYLOR COLLEGE OF MEDICINE, TX | $224,400 | ZCA1 |
| 2023 | Genome-wide synthetic lethal screening for vulnerabilities in a cell model of succinate dehydrogenase-loss paraganglioma1R21CA266999-01A1 | MAHER, LOUIS JAMES | MAYO CLINIC ROCHESTER, MN | $222,998 | ZCA1 |
| 2023 | Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer1R21CA277305-01 | HARGROVE, AMANDA ESOMARELLI, JASON ANDREW | DUKE UNIVERSITY, NC | $222,213 | ZCA1 |
| 2023 | A synthetic lethal approach for targeting p53 deficient triple negative breast cancer1R21CA273658-01A1 | MAKI, CARL G | RUSH UNIVERSITY MEDICAL CENTER, IL | $221,595 | ZCA1 |
| 2023 | ULK1 Inhibitor in Combination with Immune Checkpoint Blockade in PancreaticCancer1R21CA270588-01A1 | MACKEIGAN, JEFFREY PAUL | MICHIGAN STATE UNIVERSITY, MI | $219,491 | ZCA1 |
| 2023 | A Stem Cell Based Exosomal Vaccine for the Prevention of Cancer1R21CA277314-01 | LI, CHIYADDANAPUDI, KAVITHA | UNIVERSITY OF LOUISVILLE, KY | $219,491 | ZCA1 |
| 2023 | Preoperative immunotherapy in Hepatocellular Carcinoma1R21CA270903-01A1 | AKCE, MEHMETLESINSKI, GREGORY B. | EMORY UNIVERSITY, GA | $219,491 | ZCA1 |
| 2023 | Development of a patient-derived tumoroid culture system to explore novel medical treatments for refractory prolactinomas1R21CA264838-01A1 | HEANEY, ANTHONY P | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $218,790 | ZCA1 |
| 2023 | STK11 loss of function and anti-PD-1 therapy resistance in KRAS-driven lung adenocarcinoma1R21CA280266-01 | SEWARD, DAVID JOSEPH | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE, VT | $218,790 | ZCA1 |
| 2023 | Targeting cancer stem-like cells and inflammation for colon cancer chemoprevention1R21CA273646-01A1 | CHEN, GRACE Y.COLACINO, JUSTIN ADAM | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $218,790 | ZCA1 |
| 2023 | A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma1R21CA280433-01 | GORDON, PETER MWINTER, STUART SHELDON | CHILDREN'S HOSPITALS AND CLINICS, MN | $218,718 | ZCA1 |
| 2023 | Selective targeting of ependymoma progenitor cells via BMI1 inhibition1R21CA280148-01 | VIBHAKAR, RAJEEV | UNIVERSITY OF COLORADO DENVER, CO | $218,089 | ZCA1 |
| 2023 | Natural products inhibitors targeting homology-directed DNA repair for cancer therapy1R21CA270300-01A1 | SPIES, MARIASPIES, MICHAEL ASHLEY | UNIVERSITY OF IOWA, IA | $218,089 | ZCA1 |
| 2023 | Redox manipulation of iron to improve glioblastoma therapy: A phase 1 trial1R21CA270742-01A1 | ALLEN, BRYANBUATTI, JOHN M | UNIVERSITY OF IOWA, IA | $218,089 | ZCA1 |
| 2023 | Identification of serum protein biomarkers by profiling N-glycoproteomes of patient-derived xenografts of neuroendocrine prostate cancer1R21CA276896-01 | BROOKS, JAMES D.PITTERI, SHARON | STANFORD UNIVERSITY, CA | $217,991 | ZCA1 |
| 2023 | Novel inhibitors of oncogenic p53 mutants for lung cancer therapy.1R21CA267971-01A1 | DEB, SWATI P.WINDLE, BRAD E. | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $217,738 | ZCA1 |
| 2023 | Prevention and treatment of paclitaxel-induced peripheral neuropathy1R21CA277447-01 | LECKENBY, JONATHAN IANNOBLE, MARK D | UNIVERSITY OF ROCHESTER, NY | $215,985 | ZCA1 |
| 2023 | Mechanisms of tamoxifen-associated endometrial cancer risk1R21CA270580-01A1 | GERTZ, JASON | UNIVERSITY OF UTAH, UT | $215,869 | ZCA1 |
| 2023 | Pathomics biomarkers for stratification of clear cell kidney cancers1R21CA277381-01 | KNUDSEN, BEATRICE S | UNIVERSITY OF UTAH, UT | $215,693 | ZCA1 |
| 2023 | Multiplexed Paper-Based Blood Test for Early-Stage Colorectal Cancer Screening1R21CA270727-01A1 | BADU-TAWIAH, ABRAHAM | OHIO STATE UNIVERSITY, OH | $215,482 | ZCA1 |
| 2023 | Discovery of PPI inhibitors for the FAK FAT domain1R21CA267285-01A1 | MARLOWE, TIMOTHY ATHATCHER, GREGORY R. J | UNIVERSITY OF ARIZONA, AZ | $215,284 | ZCA1 |
| 2023 | Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancer1R21CA273983-01A1 | LAI, SAMUEL | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $214,931 | ZCA1 |
| 2023 | Amino acid transporter SLC38A5 as a drug target for TNBC: Evaluation with genetic and pharmacologic approaches1R21CA277140-01 | GANAPATHY, VADIVEL | TEXAS TECH UNIVERSITY HEALTH SCIS CENTER, TX | $214,583 | ZCA1 |
| 2023 | Mechanism Underlying Sleep Disruption by Mammary Tumors1R21CA276027-01A1 | DEVRIES, ANNE COURTNEYNELSON, RANDY J. | WEST VIRGINIA UNIVERSITY, WV | $213,180 | ZCA1 |
| 2023 | Combining BET protein inhibitors with radiation in HPV oropharyngeal cancer1R21CA267518-01A1 | IYER, GOPAL | UNIVERSITY OF WISCONSIN-MADISON, WI | $211,862 | ZCA1 |
| 2023 | Developing glycosylated RNAs as novel clinical targets for aggressive prostate cancer.1R21CA280570-01 | KERSCHER, AURORA ESQUELA | EASTERN VIRGINIA MEDICAL SCHOOL, VA | $210,375 | ZCA1 |
| 2023 | Novel modalities for prostate cancer screening: mast cells as predictors of disease, disease aggressiveness and marks of disease disparity1R21CA274021-01A1 | OSKERITZIAN, CAROLE A | UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC | $208,973 | ZCA1 |
| 2023 | Mechanism-based combination therapy for cholangiocarcinoma1R21CA273759-01A1 | YOON, KARINA J | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $208,271 | ZCA1 |
| 2023 | Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma1R21CA267394-01A1 | COBBS, CHARLES SSEARLE, BRIAN CHIH-SENG | SWEDISH MEDICAL CENTER, FIRST HILL, WA | $207,023 | ZCA1 |
| 2023 | In search of synergistic drug interactions in cancer1R21CA280567-01 | HUGHES, CHRISTOPHER C. W. | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $205,740 | ZCA1 |
| 2023 | Crosslinking-based targeted therapy for triple-negative breast cancer1R21CA280458-01 | CHEN, SHENGXICUI, XIAOJIANG | ARIZONA STATE UNIVERSITY-TEMPE CAMPUS, AZ | $202,921 | ZCA1 |
| 2023 | Drug combination nanoparticles for advanced treatment of metastatic TNBC1R21CA273739-01A1 | MU, QINGXIN | UNIVERSITY OF WASHINGTON, WA | $199,842 | ZCA1 |
| 2023 | Exploring ovarian-derived hormone STC1 as the mediator of the protective effect of breast feeding against breast cancer.1R21CA270702-01A1 | GERMAIN, DORIS A | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $197,519 | ZCA1 |
| 2023 | KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function1R21CA280233-01 | ABATE-DAGA, DANIEL | H. LEE MOFFITT CANCER CTR & RES INST, FL | $196,934 | ZCA1 |
| 2023 | Structure-Function Studies of a Cell Penetrating Antibody that Inhibits DNA Repair1R21CA278934-01 | BLEICHERT, FRANZISKAGLAZER, PETER M | YALE UNIVERSITY, CT | $195,766 | ZCA1 |
| 2023 | OR2H1 is an effective target for CAR T cells in human epithelial tumors1R21CA276205-01 | CONEJO-GARCIA, JOSE R | DUKE UNIVERSITY, NC | $195,472 | ZCA1 |
| 2023 | Defining the phenotype and cancer penetrance of CTNNA1 loss-of-function germline variants1R21CA267949-01A1 | KATONA, BRYSON WILLIAM | UNIVERSITY OF PENNSYLVANIA, PA | $195,301 | ZCA1 |
| 2023 | Modulating the immuno-metabolic interplay in liver cancer with cryoablation1R21CA274152-01A1 | COMAN, DANIEL | YALE UNIVERSITY, CT | $192,634 | ZCA1 |
| 2023 | Exercise and Lung Cancer1R21CA275978-01 | PERRY, RACHEL JAMISON | YALE UNIVERSITY, CT | $191,941 | ZCA1 |
| 2023 | Efficient and cost-effective breast cancer risk stratification using whole slide histopathology images1R21CA273665-01A1 | GURCAN, METIN NAFI | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $190,880 | ZCA1 |
| 2023 | Hypoglossal neuropathy in the pathogenesis of radiation associated dysphagia (hRAD)1R21CA273984-01A1 | HUTCHESON, KATHERINE ARNOLDSANCHEZ TERRONES, BENJAMIN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $190,380 | ZCA1 |
| 2023 | Liposome-based mRNA cancer immunotherapy targeting ion channels1R21CA277341-01 | CONFORTI, LAURA | UNIVERSITY OF CINCINNATI, OH | $189,338 | ZCA1 |
| 2023 | A combination strategy to target pathophysiology of chronic lymphocytic leukemia1R21CA259749-01A1 | GANDHI, VARSHA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $189,338 | ZCA1 |
| 2023 | Boosting anti-tumor immunity in the omentum for metastasis prevention1R21CA273656-01A1 | NAORA, HONAMI | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $189,338 | ZCA1 |
| 2023 | Quantitative Imaging of OXPHOS in Pancreatic Cancer1R21CA280238-01 | MANNING, HENRY CHARLES | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $189,338 | ZCA1 |
| 2023 | Targeting of IL-1 Signaling in Myelofibrosis1R21CA274430-01A1 | MOHI, GOLAM | UNIVERSITY OF VIRGINIA, VA | $188,753 | ZCA1 |
| 2023 | Development of pHLIP-phosphoantigen conjugates for lymphoma therapy1R21CA273042-01A1 | BAHAL, RAMANWIEMER, ANDREW J | UNIVERSITY OF CONNECTICUT STORRS, CT | $188,169 | ZCA1 |
| 2023 | Intraoperative Imaging for Lymph Node Metastases1R21CA280814-01 | YAMADA, TOHRU | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $186,883 | ZCA1 |
| 2023 | A Multi-Omics Study of the Effect and Mechanisms of Acupuncture on Psychoneurological Symptoms Among Breast Cancer Survivors1R21CA277153-01A1 | LI, HONGJIN | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $186,883 | ZCA1 |
| 2023 | Investigating GSTP1 as a novel regulator of the cysteine redoxome in breast cancer and maker of vulnerability to redox-based therapy1R21CA270876-01A1 | HELD, JASON M. | WASHINGTON UNIVERSITY, MO | $183,104 | ZCA1 |
| 2023 | Dissecting pemetrexed resistance in non-small cell lung carcinoma1R21CA277103-01 | KANG, SUMIN | EMORY UNIVERSITY, GA | $182,909 | ZCA1 |
| 2023 | Acoustic Droplet Initiated Radiosensitivity of Hepatocellular Carcinoma1R21CA273838-01A1 | EISENBREY, JOHN | THOMAS JEFFERSON UNIVERSITY, PA | $182,325 | ZCA1 |
| 2023 | Disrupting long noncoding RNA methylation to elicit antimorph behavior in breast cancer1R21CA270573-01A1 | JOHNSON, AARON M. | UNIVERSITY OF COLORADO DENVER, CO | $181,741 | ZCA1 |
| 2023 | A matrix metalloproteinase biosensor-functionalized metastasis-on-a-chip platform for evaluating adrenocortical carcinoma progression1R21CA277083-01 | DEDHIA, PRIYA HARAKHLEIGHT, JENNIFERSKARDAL, ALEKSANDER | OHIO STATE UNIVERSITY, OH | $180,933 | ZCA1 |
| 2023 | Exploration of the immunosuppressive function of RBMS3/PRRX1 axis in TNBC1R21CA273771-01A1 | GIBSON, HEATHER MARIEWU, GUOJUN | WAYNE STATE UNIVERSITY, MI | $179,988 | ZCA1 |
| 2023 | Targeting RHNO1 in Ovarian Cancer1R21CA273399-01A1 | KARPF, ADAM R. | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $179,403 | ZCA1 |
| 2023 | R21 MPI microRNA directed therapy for treating early stage pancreatic cancer1R21CA277263-01 | SCHMITTGEN, THOMAS D.ZHANG, FAN | UNIVERSITY OF FLORIDA, FL | $178,234 | ZCA1 |
| 2023 | Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor1R21CA270712-01A1 | AGOULNIK, ALEXANDER IAGOULNIK, IRINA | FLORIDA INTERNATIONAL UNIVERSITY, FL | $172,391 | ZCA1 |
| 2023 | Non-invasive assessment of graft vs host disease using optoacoustic imaging1R21CA271218-01A1 | HOLTER CHAKRABARTY, JENNIFER LINMCNALLY, LACEY R | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $169,469 | ZCA1 |
| 2023 | Role of miR-195 in Chemo-Resistant Ovarian Cancer1R21CA280507-01 | DWIVEDI, SHAILENDRA KUMAR DHAR | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $169,469 | ZCA1 |
| 2023 | Pro-Oncogenic Role of a Mitochondrial Lipid Kinase in CLL1R21CA280437-01 | GHOSH, ASISH KUMAR | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $169,469 | ZCA1 |
| 2023 | Metabolic tagging of tumor exosomes for developing enhanced exosome vaccines1R21CA270872-01A1 | WANG, HUA | UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, IL | $168,894 | ZCA1 |
| 2023 | Structural and functional analysis of a novel class of androgen receptor antagonists1R21CA280467-01 | WANG, ZHOU | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $149,651 | ZCA1 |
| 2022 | Strategies for discerning chemotherapy response and resistance in ovarian cancer1R21CA267599-01A1 | WEI, WEI | INSTITUTE FOR SYSTEMS BIOLOGY, WA | $510,364 | ZCA1 |
| 2022 | Molecular Cloaking Devices for Manipulation of Cysteine Post-Translational Modifications1R21CA273954-01 | KODADEK, THOMAS J. | UNIVERSITY OF FLORIDA, FL | $496,766 | ZCA1 |
| 2022 | A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy1R21CA260447-01A1 | LEE, RICHARD T | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $452,540 | ZCA1 |
| 2022 | Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer1R21CA262991-01A1 | KUFE, DONALD W. | DANA-FARBER CANCER INST, MA | $442,214 | ZCA1 |
| 2022 | Developing ATAC-array as a novel epigenetic biomarker to guide personalized therapy in pancreatic cancer1R21CA263285-01A1 | LEACH, STEVEN D | DARTMOUTH COLLEGE, NH | $421,689 | ZCA1 |
| 2022 | The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients1R21CA270987-01 | PERLIS, MICHAEL LLOYD | UNIVERSITY OF PENNSYLVANIA, PA | $417,828 | ZCA1 |
| 2022 | DNP-MRSI for the Detection of Latent, Treatment-Resistant Cellular Domains in HCC1R21CA263364-01A1 | GADE, TERENCE P | UNIVERSITY OF PENNSYLVANIA, PA | $416,075 | ZCA1 |
| 2022 | Developing Improved Models of Basal Cell Carcinoma to Evaluate Tumor-Drug Response1R21CA267941-01A1 | WONG, SUNNY Y | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $401,117 | ZCA1 |
| 2022 | Investigating PROTAC-mediated antigen degradation as a novel strategy to enhance cytotoxic T-cell responses against cancer in vivo.1R21CA274064-01 | SCHLIEHE, CHRISTOPHER | ERASMUS MEDICAL CENTER | $277,686 | ZCA1 |
| 2022 | Translation and validation of non-invasive measurement of PD-L1 levels with positron emission tomography (PET) in head and neck malignancies and intracranial metastases1R21CA259964-01A1 | ABOIAN, MARIAM | YALE UNIVERSITY, CT | $274,072 | ZCA1 |
| 2022 | Genomic Analysis of Cutaneous CD30+ Lymphoproliferative Disorders1R21CA259932-01A1 | QUERFELD, CHRISTIANESONG, JOO | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $266,867 | ZCA1 |
| 2022 | Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery1UH2CA267502-01 | BASU, DEVRAJ | UNIVERSITY OF PENNSYLVANIA, PA | $265,891 | ZCA1 |
| 2022 | Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes1R21CA267050-01 | MODUGNO, FRANCESMARY | MAGEE-WOMEN'S RES INST AND FOUNDATION, PA | $261,420 | ZCA1 |
| 2022 | Diapause-like adaptation of triple-negative breast cancer cells during chemotherapy treatment1R21CA267539-01 | DHIMOLEA, EUGENMITSIADES, CONSTANTINE S. | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $257,461 | ZCA1 |
| 2022 | Development of cell-based models for fibrolamellar carcinoma1R21CA274098-01 | VAKILI, KHASHAYAR | BOSTON CHILDREN'S HOSPITAL, MA | $257,222 | ZCA1 |
| 2022 | Targeting the Progesterone Receptor as a Novel Means to Increase Efficacy of Immune Checkpoint Inhibitors in Hormone Receptor Positive Breast Cancer1R21CA274044-01 | HAGAN, CHRISTYHARTMAN, ZACHARY CONRAD | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $255,588 | ZCA1 |
| 2022 | Development of Novel ERRalpha Antagonists as Breast Cancer Therapeutics1R21CA263414-01A1 | MCDONNELL, DONALD P | DUKE UNIVERSITY, NC | $254,868 | ZCA1 |
| 2022 | Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction1R21CA263455-01A1 | DELONG, MICHAEL RAYFESTEKJIAN, JACO | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $254,460 | ZCA1 |
| 2022 | Modeling and Targeting B/Myeloid Mixed Phenotype Acute Leukemia1R21CA263223-01A1 | CHEN, WENYONG | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $252,046 | ZCA1 |
| 2022 | CHEK2 loss promotes prostate cancer resistance to PARP inhibitors1R21CA267496-01A1 | JIA, LI | BRIGHAM AND WOMEN'S HOSPITAL, MA | $251,048 | ZCA1 |
| 2022 | Defining the impact of mutational drivers on the immune microenvironment of CLL1R21CA267527-01 | WU, CATHERINE JU-YINGYIN, SHANYE | DANA-FARBER CANCER INST, MA | $249,645 | ZCA1 |
| 2022 | Investigation of the impact of pegylated Interferon on clonal trajectory and inflammatory cytokine production in MPN patients1R21CA267632-01 | DUNBAR, ANDREW JEFFREYRAMPAL, RAAJIT | SLOAN-KETTERING INST CAN RESEARCH, NY | $248,243 | ZCA1 |
| 2022 | Dopamine Metabolism and Nonpharmacologic Insomnia Interventions Among Cancer Survivors1R21CA274059-01 | MAO, JUN J | SLOAN-KETTERING INST CAN RESEARCH, NY | $248,243 | ZCA1 |
| 2022 | Integrated Genotypic, Phenotypic and Immunologic Analysis of Ethnically Diverse Prostate Cancers1R21CA270862-01 | DORFF, TANYA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $246,840 | ZCA1 |
| 2022 | Gender-affirming estrogen therapy and breast cancer treatment outcome1R21CA267088-01 | HENG, YU JING JANWULF, GERBURG M | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $245,438 | ZCA1 |
| 2022 | In vivo CRISPR-screening of novel cancer cell-intrinsic targets that sensitize to local ionizing radiation, and possible combination with systemic checkpoint blockade.1R21CA267607-01A1 | WEICHSELBAUM, RALPH R | UNIVERSITY OF CHICAGO, IL | $240,831 | ZCA1 |
| 2022 | Repurposing Bazedoxifene for chemoprevention in pre-invasive pancreatic cancer IPMN1R21CA259715-01A1 | CHIO, CHRISTINE IOK IN | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $238,542 | ZCA1 |
| 2022 | Defining and targeting the epigenetic programs involved in melanoma development1R21CA267141-01 | SMALLEY, KEIRAN | H. LEE MOFFITT CANCER CTR & RES INST, FL | $236,321 | ZCA1 |
| 2022 | Characterization of the oncogenic potential of circRNAs in melanoma1R21CA267291-01 | KARRETH, FLORIAN | H. LEE MOFFITT CANCER CTR & RES INST, FL | $236,321 | ZCA1 |
| 2022 | Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases1R21CA274060-01 | SMALLEY, INNA | H. LEE MOFFITT CANCER CTR & RES INST, FL | $236,321 | ZCA1 |
| 2022 | Suppression of Prostate Cancer1R21CA262963-01A1 | LOGAN, SUSAN K. | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $236,050 | ZCA1 |
| 2022 | Development of TLR5 agonist based approaches to boost chemo-immunotherapy by modulating immunosuppressive networks1R21CA267274-01 | BRACKETT, CRAIG M. | ROSWELL PARK CANCER INSTITUTE CORP, NY | $235,901 | ZCA1 |
| 2022 | A Novel Treatment Strategy for Metastatic Breast Cancer1R21CA259719-01A1 | BAKIN, ANDREI V. | ROSWELL PARK CANCER INSTITUTE CORP, NY | $235,901 | ZCA1 |
| 2022 | DISSECTING AND TARGETING THE ROLE OF GALNT14 IN HIGH-RISK OSTEOSARCOMA1R21CA267914-01 | KOHLER, JENNIFER JYUSTEIN, JASON | BAYLOR COLLEGE OF MEDICINE, TX | $235,869 | ZCA1 |
| 2022 | Novel Prostate cancer therapy based on m-aconitase inhibition1R21CA245343-01A1 | MOORE, ANNA | MICHIGAN STATE UNIVERSITY, MI | $235,035 | ZCA1 |
| 2022 | Humanizing CXCL13 and CXCR5 in mice1R21CA256380-01A1 | LOLIS, ELIAS | YALE UNIVERSITY, CT | $234,919 | ZCA1 |
| 2022 | Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia1R21CA270912-01 | WONG, JEFFREY Y | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $233,179 | ZCA1 |
| 2022 | Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression1R21CA267138-01 | KUFE, DONALD W. | DANA-FARBER CANCER INST, MA | $232,259 | ZCA1 |
| 2022 | Tumor-specific drug activation by pericellular proteases1R21CA256460-01A1 | O'DONOGHUE, ANTHONY JOHNOWEN, SHAWN C | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $231,823 | ZCA1 |
| 2022 | Targeting defective spliceosomal pathway in myeloid malignancies1R21CA270590-01 | VISCONTE, VALERIAYANG, CHAO-YIE | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $231,699 | ZCA1 |
| 2022 | Non-invasive, image-based, in-vivo assessment of tumor hypoxia to guide hypoxia-driven adaptive radiation therapy1R21CA274426-01 | DONAHUE, MANUS JOSMUNDSON, EVAN C | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $231,643 | ZCA1 |
| 2022 | Microbiome-based biomarkers and models of lung cancer development and treatment1R21CA260382-01A1 | JOHNSON, WILLIAM EVANSEGRE, DANIEL | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $231,413 | ZCA1 |
| 2022 | Neuron-macrophage interactions in models of chemotherapy-induced peripheral neuropathy1R21CA274588-01 | GRUEBER, WESLEY BSHIN, GRACE JI-EUN | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $230,711 | ZCA1 |
| 2022 | Therapeutic targeting of MYC interactions with an essential cofactor1R21CA267540-01A1 | COLE, MICHAEL DAVID | DARTMOUTH COLLEGE, NH | $230,010 | ZCA1 |
| 2022 | Immunomodulatory effects of topical artesunate on cervical intraepithelial neoplasia 2/3.1R21CA263256-01A1 | TRIMBLE, CORNELIA L | JOHNS HOPKINS UNIVERSITY, MD | $229,659 | ZCA1 |
| 2022 | Using Canine Organoids to Advance Therapeutic Drug Development in Bladder Cancer1R21CA267372-01 | ALLENSPACH, KARINMOCHEL, JONATHAN PAUL | IOWA STATE UNIVERSITY, IA | $229,348 | ZCA1 |
| 2022 | Overcoming drug resistance using small molecule activators of protein phosphatase 2A1R21CA273979-01 | BLACK, JENNIFER D. | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $228,958 | ZCA1 |
| 2022 | Circadian regulation of cancer therapy-associated neuroinflammation1R21CA267135-01A1 | VALDEZ, ERIN G | STANFORD UNIVERSITY, CA | $228,831 | ZCA1 |
| 2022 | Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells1R21CA256009-01A1 | DONG, ZHONGYUN | UNIVERSITY OF CINCINNATI, OH | $227,205 | ZCA1 |
| 2022 | Clonal drivers of resistance to immune checkpoint blockade in liver malignancies1R21CA259799-01A1 | GENOVESE, GIANNICOLA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2022 | Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults with Cancer: A two arm pilot study1R21CA256136-01A1 | ABDI, SALAHADIN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2022 | Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML1R21CA259324-01A1 | KONOPLEVA, MARINA Y | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $227,205 | ZCA1 |
| 2022 | Enhancing CAR T therapy in multiple myeloma1R21CA267275-01 | KANG, YUBIN | DUKE UNIVERSITY, NC | $225,803 | ZCA1 |
| 2022 | Twofold Reduction in Gadolinium Dose for Brain MRI Exams using a Novel Unbalanced T1 Relaxation-Enhanced Steady-State (uT1RESS) Technique1R21CA273280-01 | EDELMAN, ROBERT R. | ENDEAVOR HEALTH CLINICAL OPERATIONS, IL | $225,803 | ZCA1 |
| 2022 | Environmental Carcinogens Induce Minority MOMP to Initiate Carcinogenesis in Lung Cancer and Mesothelioma whileMaintaining Apoptotic Resistance via Mcl-11R21CA256466-01A1 | RIPLEY, ROBERT TAYLOR | BAYLOR COLLEGE OF MEDICINE, TX | $224,400 | ZCA1 |
| 2022 | Inhibition of fatty acid amide hydrolase as a novel strategy to prevent nephrotoxicity of cisplatin.1R21CA274012-01 | LI, NINGJUN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $223,694 | ZCA1 |
| 2022 | Targeting poly (ADP ribose) polymerase (PARP) in endometrial cancer1R21CA267098-01 | WEROHA, SARAVUT | MAYO CLINIC ROCHESTER, MN | $222,998 | ZCA1 |
| 2022 | Dual anti-leukemic and cardio protective role for ROCK1R21CA263470-01A1 | KAPUR, REUBENSHI, JIANJIAN | INDIANA UNIVERSITY INDIANAPOLIS, IN | $222,296 | ZCA1 |
| 2022 | Super-Resolution Imaging of Higher-Order Heterochromatin Structure for Early Detection of Lung Carcinogenesis1R21CA259787-01A1 | LIU, YANG | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $222,122 | ZCA1 |
| 2022 | Bacterial DNA as a Diagnostic Biomarker of Hepatocellular Carcinoma1R21CA259921-01A1 | ZARRINPAR, AMIR | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $221,595 | ZCA1 |
| 2022 | Precision Genetic RNAi Medicines to Treat Metastatic Triple-Negative Breast Cancer (TNBC)1R21CA267883-01 | DOWDY, STEVEN F | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $221,595 | ZCA1 |
| 2022 | Application of in vivo humanized PDX mouse model and ex vivo organoid model to assess the therapeutic efficacy of combinatorial therapy for pseudomyxoma peritonei1R21CA259243-01A1 | LEE, YONG J | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $220,953 | ZCA1 |
| 2022 | pSer784-VCP: a clinically relevant link between autophagy and DNA damage response1R21CA263435-01A1 | SHAO, JIEYA | WASHINGTON UNIVERSITY, MO | $220,894 | ZCA1 |
| 2022 | Metabolic modulation of alkylating agent efficacy in MEK inhibitor resistant thyroid cancers.1R21CA274046-01 | PAPANDREOU, IOANNA | OHIO STATE UNIVERSITY, OH | $220,894 | ZCA1 |
| 2022 | Targeting Tryptophan Dioxygenase Degradation for Suppression of Tumor Immune Evasion1R21CA270879-01 | ALTMAN, RYAN ALIU, AIMIN | PURDUE UNIVERSITY, IN | $220,632 | ZCA1 |
| 2022 | Tumor-specific anti-angiogenic anti-CD70-FGF/VEGF-trap fusion antibodies for renal cancer therapy1R21CA263362-01A1 | MAKHOV, PETR B. | RESEARCH INST OF FOX CHASE CAN CTR, PA | $219,725 | ZCA1 |
| 2022 | Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade1R21CA266088-01 | EL-RAYES, BASSELLESINSKI, GREGORY B. | EMORY UNIVERSITY, GA | $219,491 | ZCA1 |
| 2022 | Mechanisms underlying radiation-induced dysphagia1R21CA263107-01A1 | KING, SUZANNE N. | UNIVERSITY OF LOUISVILLE, KY | $219,491 | ZCA1 |
| 2022 | Novel strategies to target lung cancer metastasis to bone1R21CA267612-01A1 | BECK, GEORGE R. | EMORY UNIVERSITY, GA | $219,491 | ZCA1 |
| 2022 | Contrast-Enhanced Ultrasound for Diagnosis and Therapy of Cholangiocarcinoma1R21CA259750-01A1 | ANTON, KEVINEISENBREY, JOHN | THOMAS JEFFERSON UNIVERSITY, PA | $218,790 | ZCA1 |
| 2022 | ER stress pathways regulate T-cell allogeneic and anti-tumor responses1R21CA263140-01A1 | YU, XUE-ZHONG | MEDICAL COLLEGE OF WISCONSIN, WI | $218,790 | ZCA1 |
| 2022 | Lymphatic delivery of immunotherapy to prevent irAEs1R21CA267263-01A1 | SEVICK, EVA M. | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $218,790 | ZCA1 |
| 2022 | Development of Novel Combination Strategies to Overcome Resistance to KRASG12C Inhibition in Colorectal Cancers1R21CA267412-01A1 | LEOPOLD, JUDITH S | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $218,790 | ZCA1 |
| 2022 | Ex vivo generation of tumor-reactive T cells for adoptive cell transfer using an immune enhanced, patient derived tumor organoid-on-a-chip (iTOC)1R21CA263137-01A1 | BEANE, JOAL DSKARDAL, ALEKSANDER | OHIO STATE UNIVERSITY, OH | $218,513 | ZCA1 |
| 2022 | CD117-Targeted Radioimmunotherapy with Astatine-211 for Acute Myeloid Leukemia and Myelodysplastic Syndrome1R21CA245598-01A1 | WALTER, ROLAND BRUNO | FRED HUTCHINSON CANCER CENTER, WA | $218,488 | ZCA1 |
| 2022 | Novel Sequencing Based Diagnostics for Leukemia in Low Resource Settings1R21CA259926-01A1 | ALEXANDER, THOMAS BLICKWANG, JEREMY R | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $218,089 | ZCA1 |
| 2022 | Impact of Obesity on Immuno-Oncology Agents in Endometrial Cancer1R21CA267584-01 | BAE-JUMP, VICTORIA LINZAMBONI, WILLIAM C | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $218,089 | ZCA1 |
| 2022 | Organoid modeling of pre-metastatic niche formation in the liver by primary colorectal tumor secreted factors1R21CA259766-01A1 | SKARDAL, ALEKSANDERTSUNG, ALLAN | OHIO STATE UNIVERSITY, OH | $218,068 | ZCA1 |
| 2022 | Mechanisms of immune control of intratumor heterogeneity and clonal competition1R21CA270610-01 | TALOS, FLAMINIA | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $217,410 | ZCA1 |
| 2022 | Effects of exercise during platinum chemotherapy on neuropathy: examining the interoceptive brain system and inflammation1R21CA259422-01A1 | KLECKNER, IAN ROBERT | UNIVERSITY OF MARYLAND BALTIMORE, MD | $216,686 | ZCA1 |
| 2022 | Targeting of eIF4A along with immunotherapy to overcome chemoresistance1R21CA256462-01A1 | RAMAN, DAYANIDHI | UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS, OH | $216,686 | ZCA1 |
| 2022 | Identification of luteolin as a BRAF-degrading molecule for developing new therapeutic agents1R21CA252393-01A1 | LIU-SMITH, FENG | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $215,985 | ZCA1 |
| 2022 | Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity1R21CA267040-01A1 | ZENT, CLIVE STEVEN | UNIVERSITY OF ROCHESTER, NY | $215,985 | ZCA1 |
| 2022 | Robust Causal Comparisons of Nonrandomized Oncology Studies1R21CA270585-01 | TAN, MING TONY | GEORGETOWN UNIVERSITY, DC | $215,910 | ZCA1 |
| 2022 | CD147-CAR-NK Cells for Hepatocellular Carcinoma Treatment1R21CA267368-01 | LIU, DONGFANG | RBHS-NEW JERSEY MEDICAL SCHOOL, NJ | $215,585 | ZCA1 |
| 2022 | DNA methylation, Liquid Biopsy, and Pancreatic Cancer1R21CA263132-01A1 | FUTSCHER, BERNARD WNELSON, MARK ANTHONYSHROFF, RACHNA | UNIVERSITY OF ARIZONA, AZ | $215,284 | ZCA1 |
| 2022 | Microbiota-mediated enhancement of the anti-tumor effect of natural killer cells1R21CA263462-01A1 | JOBIN, CHRISTIANTHOMAS, RYAN M. | UNIVERSITY OF FLORIDA, FL | $213,881 | ZCA1 |
| 2022 | Preventing Therapeutic Resistance in RAS-mutated Pediatric Cancers1R21CA267515-01 | KORTUM, ROBERT | HENRY M. JACKSON FDN FOR THE ADV MIL/MED, MD | $213,876 | ZCA1 |
| 2022 | Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers1R21CA263996-01A1 | BRODY, JONATHANSEARS, ROSALIE C | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $210,688 | ZCA1 |
| 2022 | Developing corrector small molecules for reactivation of mutant p53 in cancer1R21CA267495-01A1 | KAISER, PETERRYCHNOVSKY, SCOTT D. | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $210,003 | ZCA1 |
| 2022 | Advancing Bladder Cancer Care by Imaging and Intravesical Immune Checkpoint Blockade1R21CA263243-01A1 | TYAGI, PRADEEP | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $209,468 | ZCA1 |
| 2022 | Targeted neuroendocrine cancer therapy using Verrucarin A1R21CA256151-01A1 | JASKULA-SZTUL, RENATALIU, XIAOGUANG MARGARET | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $208,271 | ZCA1 |
| 2022 | Modeling Dynamic Immune Cell Modulation in a 3-D Tissue Engineered Platform to Enhance Patient-specific Immunotherapy for Lung Cancer1R21CA263365-01A1 | DESHANE, JESSY SATYADAS | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $208,271 | ZCA1 |
| 2022 | Exosomal Thomsen-Friedenreich glycoantigen as a new biomarker for lung cancer screening and early detection1R21CA267934-01A1 | DY, GRACERITTENHOUSE-OLSON, KATE WWU, YUN | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $207,953 | ZCA1 |
| 2022 | Targeting the ENL YEATS domain for the development of anti-leukemia agents1R21CA267512-01 | LIU, WENSHE RAY | TEXAS A&M UNIVERSITY, TX | $207,486 | ZCA1 |
| 2022 | Targeting MUC16 transactivation for ovarian cancer treatment1R21CA267570-01 | WANG, EDWARD WENGE | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $205,700 | ZCA1 |
| 2022 | The microbiome ecosystem of Barrett's esophagus and progression to cancer1R21CA259687-01A1 | PAULSON, THOMAS G | FRED HUTCHINSON CANCER CENTER, WA | $205,700 | ZCA1 |
| 2022 | Novel biologics platform for targeting tumors driven by intracellular oncoproteins1R21CA267362-01 | KOIDE, SHOHEI | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $198,103 | ZCA1 |
| 2022 | Neoadjuvant anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma1R21CA256421-01A1 | PATIL, CHIRAG GADKARYSHIAO, STEPHEN L. | CEDARS-SINAI MEDICAL CENTER, CA | $195,181 | ZCA1 |
| 2022 | R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma1R21CA273645-01 | GRINSTAFF, MARK W. | BOSTON UNIVERSITY (CHARLES RIVER CAMPUS), MA | $192,844 | ZCA1 |
| 2022 | Off-the-shelf CAR-T Therapy via Tumor-Selective Immuno-engagers1R21CA267087-01 | SNOOK, ADAMTHEVENIN, DAMIEN | LEHIGH UNIVERSITY, PA | $191,901 | ZCA1 |
| 2022 | A high-throughput screen for inhibitors of Plk1-interacting checkpoint helicase (PICH)1R21CA259718-01A1 | AZUMA, YOSHIAKICLARKE, DUNCAN J. | UNIVERSITY OF MINNESOTA, MN | $191,885 | ZCA1 |
Showing the 200 most recent of 285 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.